George has been named one of the 25 most influential people in biotech, leading Biogen for six years before leaving at the end of 2016. Sales at Biogen more than doubled under his leadership, from $4.7 billion in 2010 to $10.8 billion last year. During his tenure, he effected a turnaround by restructuring the company, divesting its Idec cancer drug division, refocusing research on neurology and hematology and presiding over the rollout of six new drugs including a blockbuster M.S. drug. His next challenge is to build Vir, founded by Bob Nelsen/Arch Ventures, which is taking on infectious diseases with more than $150MM starting commitment from Arch and Gates Foundation. Vir, which has been in stealth mode, seeks to use breakthroughs in immune programming to manipulate pathogen-host interactions. Hear from this biotech icon who has held one of the most important jobs in the industry and is reentering the startup world. Tickets.
Fireside Chat with George Scangos, former CEO Biogen; CEO Vir Biotechnology
George A. Scangos, Ph.D. has been a director since October 1996. Since July 2010, Dr. Scangos has served as Chief Executive Officer and as a member of the board of directors of Biogen Idec Inc. From October 1996 to July 2010, Dr. Scangos served as our President and Chief Executive Officer. From September 1993 to October 1996, Dr. Scangos served as President of Biotechnology at Bayer Corporation, a pharmaceutical company, and was responsible for research, business and process development,